Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.62 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.62 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.45 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31061810 | 1.00 | CYP19A1 (0.62) | CYP19A1CYP11B1CYP11B2HTTRAF1 | |
| SCHEMBL7034422 | 0.88 | TDP1 (0.54) | CYP19A1CYP11B1CYP11B2HTTRAF1 | |
| SCHEMBL3185913 | 0.84 | HTT (0.58) | CYP19A1CYP11B1CYP11B2HTTTDP1 | |
| SCHEMBL4073859 | 0.84 | CYP19A1 (0.69) | CYP19A1CYP11B1CYP11B2HTTTDP1 | |
| SCHEMBL16370879 | 0.84 | HTT (0.51) | CYP19A1CYP11B1CYP11B2HTTTDP1 | |
| SCHEMBL1492729 | 0.83 | KMT2A (0.50) | CYP19A1CYP11B1CYP11B2HTTTDP1 | |
| SCHEMBL2184978 | 0.82 | HTT (0.49) | CYP19A1CYP11B1CYP11B2HTTTDP1 | |
| SCHEMBL16371403 | 0.82 | HTT (0.56) | CYP19A1CYP11B1CYP11B2HTTTDP1 | |
| SCHEMBL7632075 | 0.82 | HTT (0.55) | HTTTDP1PKMKMT2ALMNA | |
| SCHEMBL11697350 | 0.82 | HTT (0.55) | CYP19A1CYP11B1CYP11B2HTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195452-B2 | N-(4-(oxazol-5-yl)phenyl) chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases | ENDOGENA THERAPEUTICS, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| EP-3902798-B1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS INC (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-3902798-B1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS INC (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20220089583-A1 | N-(4-(OXAZOL-5-YL)PHENYL) CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| US-20220089547-A1 | COMPOUNDS FOR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| US-20220089583-A1 | N-(4-(OXAZOL-5-YL)PHENYL) CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| EP-3902606-A1 | COMPOUNDS FOR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF NEURORETINAL DISEASES | Endogena Therapeutics, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3902798-A1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | Endogena Therapeutics, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| CN-113301958-A | Compounds for use as therapeutically active substances in the treatment and/or prevention of neuroretinal diseases | 内生疗法公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-113227086-A | N- (4- (oxazol-5-yl) phenyl) chroman-3-carboxamide derivatives and related compounds as stimulators of production of retinal precursor cells for the treatment of neuroretinal diseases | 内生疗法公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20200207719-A1 | COMPOUNDS FOR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT OF RETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| WO-2020140050-A1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020140043-A1 | COMPOUNDS FOR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| US-20200207749-A1 | COMPOUNDS FOR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT OF RETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200207749-A1 | COMPOUNDS FOR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT OF RETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| WO-2020140043-A1 | COMPOUNDS FOR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| US-20200207719-A1 | COMPOUNDS FOR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT OF RETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| WO-2020140050-A1 | N-(4-(OXAZOL-5-YL)PHENYL)CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | ENDOGENA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| US-20090270450-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | US | disclosed |
| WO-2004046118-A2 | 2-4-(DI-PHENYL-AMINO)-PYRIMIDINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089547-A1 | COMPOUNDS FOR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF NEURORETINAL DISEASES | ALDH1A2, NR2E3, BDNF | CYP19A1 4211/4885CYP11B1 383/4885CYP11B2 328/4885 |
| US-20200207749-A1 | COMPOUNDS FOR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT OF RETINAL DISEASES | ALDH1A2, NR2E3, ARRB1 | CYP19A1 4754/4885CYP11B1 945/4885CYP11B2 764/4885 |
| US-20200207719-A1 | COMPOUNDS FOR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT OF RETINAL DISEASES | ALDH1A2, NR2E3, PDE6D | CYP19A1 4452/4885CYP11B1 464/4885CYP11B2 337/4885 |
| US-12195452-B2 | N-(4-(oxazol-5-yl)phenyl) chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases | NR2E3, GFRA2, ALDH1A2 | CYP19A1 3982/4885CYP11B1 953/4885CYP11B2 539/4885 |
| US-20220089583-A1 | N-(4-(OXAZOL-5-YL)PHENYL) CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | NR2E3, GFRA2, ALDH1A2 | CYP19A1 3982/4885CYP11B1 953/4885CYP11B2 539/4885 |
| US-20090270450-A1 | CHEMICAL COMPOUNDS | CSF1R, CSF3R, FLT3 | CYP19A1 1835/4885CYP11B1 2601/4885CYP11B2 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.